×
Cara Therapeutics Operating Expenses 2012-2024 | CARA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cara Therapeutics operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Cara Therapeutics Operating Expenses 2012-2024 | CARA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cara Therapeutics operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.5B
Vertex Pharmaceuticals (VRTX)
$119.5B
Regeneron Pharmaceuticals (REGN)
$114.6B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$101.6B
CSL (CSLLY)
$97.4B
GSK (GSK)
$84.8B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.4B
Biogen (BIIB)
$28.2B
BioNTech SE (BNTX)
$28B
Moderna (MRNA)
$24.6B
Illumina (ILMN)
$21.1B
BeiGene (BGNE)
$20.7B
Genmab (GMAB)
$16B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$12.6B
Incyte (INCY)
$12.5B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$12.4B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.6B
Roivant Sciences (ROIV)
$8.6B
Legend Biotech (LEGN)
$8.5B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$7.7B
Exelixis (EXEL)
$7.5B